WHC is still in active development. Read this to understand our approach.
depiction of CFMRIVODIXTERW-UHFFFAOYSA-N.svg
isomerdesign

HU-308

Verificar en isomerdesign

isomerdesign

HU-433

Verificar en isomerdesign

drugmap

PRS-211375 iv

Verificar en drugmap

drugmap

PRS-211375 iv

Verificar en drugmap

wiki

HU-308

Verificar en wiki

Data

InChI: InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3

Sinónimos: HU-308, Oral Cannabinor (pain), Pharmos,HU-433, CB2-selective cannabinoid platform, Pharmos, Bicyclic cannabinoids, Pharmos, HU-308, PRS-211058, CB2 activator (osteoporosis), Yissum,[(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol, PRS-211359, PRS-211375 (iv, inflammation/autoimmune disease), Pharmos, PRS-211375,CB2 activator (osteoporosis), PRS-211335, PRS-211375 (oral, pain), Pharmos, PRS-211096,Cannabinor

Estimated data

Solubilidad: -6.817 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 85.3% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.